Dr. Frank Chen, MD

Pain Medicine Orange, TX Male
NPI: 1497882583
Total Payments
$2,539
2024 Payments
$214.30
Companies
29
Transactions
148
Medicare Patients
12,644
Medicare Billing
$3.5M

Payment Breakdown by Category

Food & Beverage$2,504 (98.6%)
Education$35.00 (1.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $2,504 146 98.6%
Education $35.00 2 1.4%

Top Paying Companies

Company Total Records Latest Year
Collegium Pharmaceutical, Inc. $424.63 26 $0 (2024)
Daiichi Sankyo Inc. $407.01 33 $0 (2019)
Purdue Pharma L.P. $255.74 16 $0 (2018)
Indivior Inc. $216.78 10 $0 (2024)
Pernix Therapeutics Holdings, Inc. $183.01 11 $0 (2018)
Arbor Pharmaceuticals, Inc. $156.69 8 $0 (2020)
Sentynl Therapeutics, Inc. $120.75 9 $0 (2019)
Sunovion Pharmaceuticals Inc. $110.84 2 $0 (2022)
Takeda Pharmaceuticals U.S.A., Inc. $70.05 1 $0 (2018)
BioDelivery Sciences International, Inc. $56.57 4 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $214.30 9 Indivior Inc. ($79.38)
2023 $134.10 7 Collegium Pharmaceutical, Inc. ($67.53)
2022 $279.98 12 Sunovion Pharmaceuticals Inc. ($110.84)
2021 $171.43 10 Collegium Pharmaceutical, Inc. ($54.86)
2020 $225.74 12 Collegium Pharmaceutical, Inc. ($82.17)
2019 $262.19 16 Sentynl Therapeutics, Inc. ($82.73)
2018 $739.64 53 Daiichi Sankyo Inc. ($196.73)
2017 $511.84 29 Purdue Pharma L.P. ($166.51)

All Payment Transactions

148 individual payment records from CMS Open Payments — Page 1 of 6

Date Company Product Nature Form Amount Type
10/16/2024 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $16.65 General
Category: Opioid Analgesic
09/25/2024 VERTEX PHARMACEUTICALS INCORPORATED — Food and Beverage In-kind items and services $29.43 General
06/12/2024 Medtronic, Inc. INTELLIS ADAPTIVESTIM (Device) Food and Beverage In-kind items and services $21.72 General
Category: Spinal Cord Neurostimulation
05/22/2024 Collegium Pharmaceutical, Inc. Nucynta (Drug) Food and Beverage Cash or cash equivalent $20.17 General
Category: Opioid Analgesic
03/11/2024 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $17.86 General
Category: Opioid Analgesic
03/05/2024 Indivior Inc. SUBLOCADE (Drug) Food and Beverage In-kind items and services $22.49 General
Category: OUD
02/27/2024 Indivior Inc. SUBLOCADE (Drug) Food and Beverage In-kind items and services $28.56 General
Category: OUD
02/12/2024 Indivior Inc. SUBLOCADE (Drug) Food and Beverage In-kind items and services $28.33 General
Category: OUD
01/25/2024 Braeburn Inc. BRIXADI (Drug) Food and Beverage In-kind items and services $29.09 General
Category: Opioid Use Disorder
11/21/2023 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $15.40 General
Category: Opioid Analgesic
11/07/2023 Tris Pharma Inc Dyanavel XR (Drug) Food and Beverage In-kind items and services $23.83 General
Category: ADHD
10/16/2023 Braeburn Inc. BRIXADI (Drug) Food and Beverage In-kind items and services $18.52 General
Category: Opioid Use Disorder
07/25/2023 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $18.06 General
Category: Opioid Analgesic
07/20/2023 Kowa Pharmaceuticals America, Inc. SEGLENTIS (Drug) Food and Beverage In-kind items and services $24.22 General
Category: PAIN MANAGEMENT
06/14/2023 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $17.33 General
Category: Opioid Analgesic
01/10/2023 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $16.74 General
Category: Opioid Analgesic
12/14/2022 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $18.43 General
Category: Opioid Analgesic
11/10/2022 Biohaven Pharmaceutical Holding Company Ltd. NURTEC ODT (Drug) Food and Beverage In-kind items and services $15.56 General
Category: PRIMARY CARE
10/17/2022 Collegium Pharmaceutical, Inc. XTAMPZA (Drug) Food and Beverage Cash or cash equivalent $13.66 General
Category: Opioid Analgesic
09/07/2022 Sunovion Pharmaceuticals Inc. — Food and Beverage In-kind items and services $89.68 General
07/19/2022 Hikma Pharmaceuticals USA Kloxxado (Drug) Education In-kind items and services $21.00 General
Category: Pulmonary/Respiratory Diseases
07/19/2022 Hikma Pharmaceuticals USA Kloxxado (Drug) Education In-kind items and services $14.00 General
Category: Pulmonary/Respiratory Diseases
06/14/2022 Sunovion Pharmaceuticals Inc. — Food and Beverage In-kind items and services $21.16 General
06/02/2022 GRT US Holding, Inc. Qutenza (Drug) Food and Beverage In-kind items and services $15.58 General
Category: Pain Management
04/28/2022 GRT US Holding, Inc. Qutenza (Drug) Food and Beverage In-kind items and services $15.55 General
Category: Pain Management
123…6»

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 12 2,610 9,312 $1.7M $683,849
2022 10 3,211 11,370 $2.0M $814,004
2021 10 3,387 13,301 $2.5M $1.1M
2020 11 3,436 12,497 $2.5M $993,656
Total Patients
12,644
Total Services
46,480
Medicare Billing
$3.5M
Procedure Codes
43

All Medicare Procedures & Services

43 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 536 2,504 $510,816 $214,231 41.9%
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2023 270 701 $245,250 $107,575 43.9%
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2023 206 553 $221,200 $105,952 47.9%
80307 Testing for presence of drug, by chemistry analyzers Office 2023 492 1,569 $313,800 $94,799 30.2%
G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes Office 2023 533 2,676 $200,700 $65,685 32.7%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 202 800 $139,200 $51,704 37.1%
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2023 163 293 $73,700 $32,542 44.2%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 47 47 $14,899 $5,679 38.1%
99212 Established patient office or other outpatient visit, 10-19 minutes Office 2023 41 48 $5,520 $1,967 35.6%
96132 Evaluation of neuropsychological test, first hour Office 2023 16 16 $5,360 $1,596 29.8%
G0444 Annual depression screening, 5 to 15 minutes Office 2023 65 65 $2,925 $1,129 38.6%
96138 Administration of psychological or neuropsychological test by technician, first 30 minutes Office 2023 39 40 $3,800 $990.09 26.1%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 583 2,856 $582,624 $257,998 44.3%
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2022 454 1,120 $280,000 $124,953 44.6%
80307 Testing for presence of drug, by chemistry analyzers Office 2022 550 1,981 $396,200 $120,071 30.3%
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2022 392 601 $240,400 $116,094 48.3%
G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes Office 2022 595 3,502 $262,665 $90,728 34.5%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 251 834 $145,146 $50,835 35.0%
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2022 188 260 $91,000 $39,807 43.7%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 81 81 $25,677 $9,551 37.2%
99212 Established patient office or other outpatient visit, 10-19 minutes Office 2022 57 75 $8,625 $2,909 33.7%
G0444 Annual depression screening, 15 minutes Office 2022 60 60 $2,700 $1,057 39.2%
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms Office 2021 594 2,302 $920,800 $452,165 49.1%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 586 2,334 $476,136 $217,197 45.6%
80307 Testing for presence of drug, by chemistry analyzers Office 2021 595 2,305 $461,000 $141,651 30.7%
12»

About Dr. Frank Chen, MD

Dr. Frank Chen, MD is a Pain Medicine healthcare provider based in Orange, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1497882583.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Chen, MD has received a total of $2,539 in payments from pharmaceutical and medical device companies, with $214.30 received in 2024. These payments were reported across 148 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($2,504).

As a Medicare-enrolled provider, Chen has provided services to 12,644 Medicare beneficiaries, totaling 46,480 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.

Practice Information

  • Specialty Pain Medicine
  • Location Orange, TX
  • Active Since 02/27/2007
  • Last Updated 02/01/2016
  • Taxonomy Code 207LP2900X
  • Entity Type Individual
  • NPI Number 1497882583

Products in Payments

  • XTAMPZA (Drug) $297.07
  • Morphabond ER (Drug) $286.23
  • SUBLOCADE (Drug) $192.99
  • ZOHYDRO ER (Drug) $183.01
  • Horizant (Drug) $156.69
  • Movantik (Drug) $152.12
  • SYMPROIC (Drug) $97.62
  • Levorphanol Tartrate (Drug) $82.73
  • HYSINGLA ER (Drug) $81.71
  • Uloric (Drug) $70.05
  • Xtampza ER (Drug) $61.35
  • BRIXADI (Drug) $47.61
  • Nucynta (Drug) $39.31
  • Levorphanol (Drug) $38.02
  • Kloxxado (Drug) $35.00
  • Qutenza (Drug) $31.13
  • ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $29.95
  • BELBUCA (Drug) $29.02
  • BUNAVAIL 2.1 mg 30-count box (Drug) $27.55
  • QULIPTA (Drug) $26.81

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pain Medicine Doctors in Orange

Dr. Andrew Germanovich, D.o., M.s, D.O., M.S

Pain Medicine — Payments: $660,862

Pain Medicine $660,862

Dr. Eric Chang, M.d, M.D

Pain Medicine — Payments: $45,901

Pain Medicine $45,901

Rachel Sunico

Pain Medicine — Payments: $5,153

Pain Medicine $5,153

Dr. Ly Zhang, Md, MD

Pain Medicine — Payments: $2,914

Pain Medicine $2,914

Asif Jillani, M.d, M.D

Pain Medicine — Payments: $1,719

Pain Medicine $1,719

Eric Heyer, Md, MD

Pain Medicine — Payments: $1,491

Pain Medicine $1,491